STATCenter·
STAT+: Lilly’s Jaypirca approved as first-line CLL therapy
Eli Lilly’s Jaypirca has won FDA approval for previously untreated chronic lymphocytic leukemia and small lymphocytic lymphoma.
Read at STAT →
Health · 1 sources covering this
STAT+: Lilly’s Jaypirca approved as first-line CLL therapy
Eli Lilly’s Jaypirca has won FDA approval for previously untreated chronic lymphocytic leukemia and small lymphocytic lymphoma.
Coverage spectrum
0 L · 1 C · 0 R
How 1 sources are covering this
Embed this bias spectrum on your site
Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.
<iframe src="https://statesidedaily.com/embed/cluster/76a0c8e3ee9fecf97d7fa037e0d994f8754a3171" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="STAT+: Lilly’s Jaypirca approved as first-line CLL therapy"></iframe>
